Goldman Sachs reissued their sell rating on shares of Johnson & Johnson (NYSE:JNJ) in a report released on Wednesday morning, MarketBeat reports. Goldman Sachs currently has a $102.00 price objective on the stock, up from their prior price objective of $100.00.

Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.07% during midday trading on Wednesday, hitting $104.37. 9,803,467 shares of the stock were exchanged. The firm has a 50 day moving average of $100.74 and a 200 day moving average of $98.69. Johnson & Johnson has a 12-month low of $81.79 and a 12-month high of $105.49. The firm has a market cap of $292.58 billion and a P/E ratio of 19.05.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, January 26th. The company reported $1.44 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.42 by $0.02. During the same period in the previous year, the company posted $1.27 earnings per share. The business earned $17.80 billion during the quarter, compared to analyst estimates of $17.88 billion. Johnson & Johnson’s revenue was down 2.4% compared to the same quarter last year. Equities analysts forecast that Johnson & Johnson will post $6.50 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 8th. Shareholders of record on Tuesday, February 23rd will be issued a dividend of $0.75 per share. The ex-dividend date is Friday, February 19th. This represents a $3.00 annualized dividend and a yield of 2.87%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.61.

Other institutional investors recently made changes to their positions in the company. Creative Planning bought a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $0. Lowe FS increased its stake in shares of Johnson & Johnson by 15.2% in the third quarter. Lowe FS now owns 379 shares of the company’s stock valued at $35,000 after buying an additional 50 shares during the last quarter. Lenox Wealth Advisors increased its stake in shares of Johnson & Johnson by 5.9% in the fourth quarter. Lenox Wealth Advisors now owns 1,065 shares of the company’s stock valued at $109,000 after buying an additional 59 shares during the last quarter. Peavine Capital Management increased its stake in shares of Johnson & Johnson by 0.3% in the fourth quarter. Peavine Capital Management now owns 2,480 shares of the company’s stock valued at $255,000 after buying an additional 7 shares during the last quarter. Finally, Berson & Corrado Investment Advisors bought a new stake in shares of Johnson & Johnson during the fourth quarter valued at about $261,000.

A number of other analysts have also commented on the stock. Independent Research GmbH set a $108.00 price objective on shares of Johnson & Johnson and gave the company a neutral rating in a research note on Wednesday, January 27th. Leerink Swann reaffirmed an outperform rating and set a $120.00 price objective (up from $115.00) on shares of Johnson & Johnson in a research note on Wednesday, January 27th. Vetr lowered shares of Johnson & Johnson from a buy rating to a hold rating and set a $105.00 price objective for the company. in a research note on Tuesday, January 26th. Credit Suisse reaffirmed a neutral rating on shares of Johnson & Johnson in a research note on Monday, January 25th. Finally, Raymond James reaffirmed an outperform rating and set a $105.00 price objective (down from $108.00) on shares of Johnson & Johnson in a research note on Friday, January 22nd. One analyst has rated the stock with a sell rating, ten have given a hold rating and ten have assigned a buy rating to the stock. The company has a consensus rating of Hold and a consensus target price of $107.83.

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Company’s research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

12 Month Chart for NYSE:JNJ

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.